Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study

R. Advani, N. Talreja, R. Tibshirani, S. Zhao, A. Alizadeh, J. Briones, R. Bordes, J. Cohen, S. Horning, R. Levy, IS. Lossos, Y. Natkunam

Blood (2008) 112 (11): 3769.

https://doi.org/10.1182/blood.V112.11.3769.3769

Published: 2008

Journal Articles

Non Myeloablative Allogeneic Related Transplant in Patients with Aggressive B Cell Lymphoma: Results of Two Multicenter Spanish Trials. The GELTAMO Group.

M.D. Caballero, J. Briones, M.V Mateos, J.F. Tomás, R. Martino, J. de la Serna, J.L. Díez, J.A. Pérez-Simón, A. Sureda, J. Sarrá, J. García-Laraña, J.M. Ribera, J. Sierra, J.F. San Miguel

Blood (2007) 110 (11): 5053.

https://doi.org/10.1182/blood.V110.11.5053.5053

Published: 2007

Journal Articles

Identification of Neoplastic Infiltration of the Cerebrospinal Fluid (CSF) in Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma (B-NHL) without Clinical Evidence of Leptomeningeal Disease: A Comparative Analysis of the Utility of Flow Cytometry (FCM) Versus Conventional Cytology (CC).

A. Orfao, MD, PhD, S. Quijano, MSc, A. Lopez, BSc, G. Deben, MD, A. Salar, MD, C. Poderos, MD, J.M. Sancho, MD, C. Vallejo, MD, J. Arias, MD, J.A. Garcia, MD, F. Capote, MD, M. Morado, MD, C. Nicolas, MD, J. Briones, MD, S. Fernandez, MD, A. Carmona, MD, L. Vazquez, MD, J.F. San Miguel, MD, PhD

Blood (2006) 108 (11): 4605.

https://doi.org/10.1182/blood.V108.11.4605.4605

Published: 2006

Journal Articles

Non Myeloablative Transplant in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

M.D. Caballero, R. Martino, M.V. Mateos, J. Briones, J. de la Serna, J.F. Tomas, R. Arranz, J.L. Diez, V. Rubio, Josep Maria Ribera, J.M. Moraleda, G. Sanz, A. Urbano, J. Sarrá, A. Sampol, J. Sierra

Blood (2004) 104 (11): 2318.

https://doi.org/10.1182/blood.V104.11.2318.2318

Published: 2004

Journal Articles

Allogeneic Transplant with Reduced Intensity Conditioning Regimens (RIC) Could Reverse Poor Prognosis of Unmutated Igvh, 11q- or 17p- Abnormalities in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

M.D. Caballero, J.A. García-Marco, R. Martino, M.V. Mateos, R. Cabrera, J. Briones, M. González, J. Esteve, A. León, Josep Maria Ribera, J. Sarrá, J. de la Serna, J.F. San Miguel

Blood (2004) 104 (11): 2319.

https://doi.org/10.1182/blood.V104.11.2319.2319

Published: 2004

Journal Articles

First-Line Treatment with R-Chop/21 for Patients with Disseminated Diffuse Large B-Cell Lymphoma (DLCL). Results of a Prospective Series of 128 Patients.

E. Gonzalez-Barca, PhD, E. Domingo-Domenech, MD, J. M. Ribera, PhD, J. Briones, PhD, A. Salar, PhD, L. Gallur, MD, C. Estany, MD, L. Escoda, MD, S. Gardella, MD, J. A. Hernandez, MD, J. Rodriguez, MD, E. Ramila, MD, O. Ramon, MD, M. Garcia-Pinto, MD, I. Español, PhD, P. Vivancos, MD, A. Asensio, MD, M. Encuentra, A. Fernandez de Sevilla, PhD

Blood (2004) 104 (11): 4573.

https://doi.org/10.1182/blood.V104.11.4573.4573

Published: 2004

Journal Articles

First-Line Treatment with Rituximab Improves Survival of Patients with Post-Transplant Lymphoproliferative Disease (PTLD).

E. Gonzalez-Barca, PhD, E. Domingo-Domenech, MD, J. Gomez-Codina, MD, F. Capote, MD, E. Flores, MD, J. Briones, PhD, A. Salar, PhD, C. Panizo, MD, C. Montalban, PhD, J. M. Ribera, PhD, D. Caballero, PhD, A. Muñoz, MD, L. Gallur, MD, M.A. Canales, MD, P. Fernandez, MD, M. Encuentra, A. Fernandez de Sevilla, PhD

Blood (2004) 104 (11): 1406.

https://doi.org/10.1182/blood.V104.11.1406.1406

Published: 2004

NARROW

LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study

Non Myeloablative Allogeneic Related Transplant in Patients with Aggressive B Cell Lymphoma: Results of Two Multicenter Spanish Trials. The GELTAMO Group.

Identification of Neoplastic Infiltration of the Cerebrospinal Fluid (CSF) in Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma (B-NHL) without Clinical Evidence of Leptomeningeal Disease: A Comparative Analysis of the Utility of Flow Cytometry (FCM) Versus Conventional Cytology (CC).

Non Myeloablative Transplant in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

Allogeneic Transplant with Reduced Intensity Conditioning Regimens (RIC) Could Reverse Poor Prognosis of Unmutated Igvh, 11q- or 17p- Abnormalities in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

First-Line Treatment with R-Chop/21 for Patients with Disseminated Diffuse Large B-Cell Lymphoma (DLCL). Results of a Prospective Series of 128 Patients.

First-Line Treatment with Rituximab Improves Survival of Patients with Post-Transplant Lymphoproliferative Disease (PTLD).

Email alerts

ASH Publications

American Society of Hematology

LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study

Non Myeloablative Allogeneic Related Transplant in Patients with Aggressive B Cell Lymphoma: Results of Two Multicenter Spanish Trials. The GELTAMO Group.

Identification of Neoplastic Infiltration of the Cerebrospinal Fluid (CSF) in Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma (B-NHL) without Clinical Evidence of Leptomeningeal Disease: A Comparative Analysis of the Utility of Flow Cytometry (FCM) Versus Conventional Cytology (CC).

Non Myeloablative Transplant in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.

Allogeneic Transplant with Reduced Intensity Conditioning Regimens (RIC) Could Reverse Poor Prognosis of Unmutated Igvh, 11q- or 17p- Abnormalities in B-Cell Chronic Lymphocytic Leukemia (B-CLL).

First-Line Treatment with R-Chop/21 for Patients with Disseminated Diffuse Large B-Cell Lymphoma (DLCL). Results of a Prospective Series of 128 Patients.

First-Line Treatment with Rituximab Improves Survival of Patients with Post-Transplant Lymphoproliferative Disease (PTLD).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only